Werewolf Q2 net income $3.7M on $21M asset sale; cash runway into Q2 2027

Werewolf Therapeutics, Inc.

Net income of $3.7M vs net loss of $18.0M in Q2 2025; collaboration revenue of $21.0M from JZP898 sale to Jazz.
Cash and equivalents $22.0M as of June 30, 2026, down from $46.5M at March 31, 2026; expects to fund operations into Q2 2027.
R&D expenses decreased to $6.2M from $13.1M; G&A increased to $7.7M from $4.4M.
Exploring strategic alternatives with Piper Sandler; expects data updates on WTX-124 and WTX-330 in H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.